Investor Relations

Who is BrainsWay?

BrainsWay is a commercial stage medical device company focused on the development and sale of non-invasive neurostimulation products using the Company’s proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology.

The Company received marketing authorization from the U.S. Food and Drug Administration (FDA) for its products for a variety of patient populations, including in 2013 for patients with major depressive disorder (MDD), in 2018 for patients with obsessive-compulsive disorder (OCD), and in 2020 for patients with smoking addiction.

BrainsWay is currently conducting clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders.

Latest Releases

October 12, 2021

BrainsWay Announces Prominent Addition to Scientific Advisory Board

Zafiris Daskalakis, MD, PhD to Bring Extensive Research and Clinical Expertise to Assist in Guiding Growth and Clinical Impact Strategy BURLINGTON, Mass. and JERUSALEM, Oct. 12, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay" or the “Company”), a global leader in advanced

Read More

September 30, 2021

BrainsWay Announces Data Published in World Psychiatry on Deep Transcranial Magnetic Stimulation (Deep TMS™) for Smoking Addiction

Evidence Supports Use of Deep TMS as a Safe and Effective Treatment for Smoking Addiction BURLINGTON, Mass. and JERUSALEM, Sept. 30, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay'' or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for

Read More

September 9, 2021

BrainsWay to Participate in Two Upcoming Investor Conferences

BURLINGTON, Mass. and JERUSALEM, Sept. 09, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that Christopher von Jako, Ph.D., President and

Read More

For more information please contact:

Tel: +1-844-386-7001
Tel: +972-2-647-6010
Email: ir@brainsway.com